Can Shire's new Mydayis, its latest Adderall iteration, really nab $500M in sales?
admin 21st June 2017 Uncategorised 0Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it’s targeting $500 million in sales by 2020. The company will have to persuade payers that a more convenient version of Shire’s old standby Adderall is worth a brand price.
More: Can Shire's new Mydayis, its latest Adderall iteration, really nab 0M in sales?
Source: fierce